Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in ...
Dr. Chiara Ciccarese discusses the TACITO-II trial results on fecal microbiota transplantation (FMT) vs. placebo in metastatic renal cell carcinoma patients receiving pembrolizumab plus axitinib. FMT increased one-year progression-free survival (PFS) rate to 66.7% from 35%, meeting the primary endpoint. The procedure, performed via colonoscopy and oral capsules, was safe and feasible, with 90% dose intensity achieved. Future research will analyze microbiota composition and potential for phase III trials.
Reference News
Dr. Chiara Ciccarese discusses the TACITO-II trial results on fecal microbiota transplantation (FMT) vs. placebo in metastatic renal cell carcinoma patients receiving pembrolizumab plus axitinib. FMT increased one-year progression-free survival (PFS) rate to 66.7% from 35%, meeting the primary endpoint. The procedure, performed via colonoscopy and oral capsules, was safe and feasible, with 90% dose intensity achieved. Future research will analyze microbiota composition and potential for phase III trials.